De Oliveira Denis Francisco Gonçalves, Abreu João Pedro Braga De Sousa, De Aguiar Rairam Fernandes, Assef Alexia Nathália Brígido, Foschetti Danielle Abreu, Bezerra Thâmara Manoela Marinho, Viana Khalil Fernandes, Feitosa Sthefane Gomes, Pereira Karuza Maria Alves
Department of Pathology and Legal Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Department of Clinical Dentistry, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará, Fortaleza, Brazil.
Asian Pac J Cancer Prev. 2025 Jul 1;26(7):2257-2265. doi: 10.31557/APJCP.2025.26.7.2257.
The tumor-stroma ratio (TSR) has emerged as a potential prognostic marker in several cancers, including oral squamous cell carcinoma (OSCC). However, results with high certainty of evidence are required for its implementation in routine histological analysis. Therefore, this systematic review aims to summarize the evidence on the prognostic role of the TSR in OSCC.
A search was performed in Embase, PubMed, Scopus, Livivo, Web of Science, and Google Scholar. We included cohort studies that evaluated the association between TSR and survival. Reviews and studies that did not report hazard ratio (HR) were excluded.
This systematic review included 10 studies and showed an association between TSR and survival. Low TSR (stroma-rich) was associated with decreased overall survival (OS) in univariate analysis (HR = 3.00, 95% CI: 1.69-5.30, p<0.01) and multivariate analysis (HR = 2.91, 95% CI: 2.19-3.87, p<0.01); poorer disease-specific survival (DSS) in univariate analysis (HR = 2.57, 95% CI: 1.95-3.39, p<0.01) and multivariate analysis (HR = 2.64, 95% CI: 1.83-3.79, p<0.01); and poorer disease-free survival (DFS) in univariate (HR = 2.56, 95% CI: 2.02-3.23, p<0.01) and multivariate analyses (HR = 2.11, 95% CI: 1.74-2.56, p<0.01).
Our findings indicate that TSR is an independent prognostic factor for OS, DSS, and DFS in oral squamous cell carcinoma. However, future studies are needed to assess the prognostic role of this histopathological parameter in OSCC to increase the certainty of the evidence.
肿瘤-基质比(TSR)已成为包括口腔鳞状细胞癌(OSCC)在内的多种癌症的潜在预后标志物。然而,要将其应用于常规组织学分析,需要有高度确定性的证据结果。因此,本系统评价旨在总结TSR在OSCC中预后作用的证据。
在Embase、PubMed、Scopus、Livivo、Web of Science和谷歌学术中进行了检索。我们纳入了评估TSR与生存之间关联的队列研究。未报告风险比(HR)的综述和研究被排除。
本系统评价纳入了10项研究,显示TSR与生存之间存在关联。低TSR(富含基质)在单因素分析(HR = 3.00,95%CI:1.69 - 5.30,p<0.01)和多因素分析(HR = 2.91,95%CI:2.19 - 3.87,p<0.01)中与总生存期(OS)降低相关;在单因素分析(HR = 2.57,95%CI:1.95 - 3.39,p<0.01)和多因素分析(HR = 2.64,95%CI:1.83 - 3.79,p<0.01)中与疾病特异性生存期(DSS)较差相关;在单因素(HR = 2.56,95%CI:2.02 - 3.23,p<0.01)和多因素分析(HR = 2.11,95%CI:1.74 - 2.56,p<0.01)中与无病生存期(DFS)较差相关。
我们的研究结果表明,TSR是口腔鳞状细胞癌中OS、DSS和DFS的独立预后因素。然而,需要进一步的研究来评估这一组织病理学参数在OSCC中的预后作用,以提高证据的确定性。